Market research
OCC.AU Orthocell Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 193M
- P/E ratio
- Not available
- Analyst target
- 1.14
- Dividend yield
- Not available
- Beta
- -0.06
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000OCC6
- Market cap
- 193M
- P/E ratio
- Not available
- Analyst target
- 1.14
- Dividend yield
- Not available
- Beta
- -0.06
About
About Orthocell Limited
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; OrthoATI, for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for bone, nerve, tendon, muscle, or scar tissue, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OCC.AU discussion.
5 years, 5 months ago
Orthocell Limited is currently in a long term uptrend where the price is trading 18.8% above its 200 day moving average.
From a valuation standpoint, the stock is 57.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 109.7.
Orthocell Limited's total revenue rose by 57.7% to $637K since the same quarter in the previous year.
Its net income has dropped by 110.6% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 37.4% to $-2M since the same quarter in the previous year.
Based on the above factors, Orthocell Limited gets an overall score of 4/5.